Capricor Therapeutics Inc
|
PUT
|
$5.48 Billion
|
65.7K
|
Q2 2025
New holding
|
|
|
|
PUT
|
$3.31 Billion
|
128K
|
Q2 2025
Added 37000.58%
|
|
Moonlake Immunotherapeutics
|
PUT
|
$1.48 Billion
|
45.5K
|
Q2 2025
New holding
|
|
|
|
PUT
|
$1.21 Billion
|
45.5K
|
Q2 2025
Added 19674.78%
|
|
Mereo Biopharma Group PLC
|
PUT
|
$1.03 Billion
|
2.3K
|
Q2 2025
Added 2430.77%
|
|
|
|
PUT
|
$915 Million
|
659K
|
Q2 2025
Added 549410.81%
|
|
|
|
PUT
|
$792 Million
|
19.1K
|
Q2 2025
New holding
|
|
|
|
PUT
|
$698 Million
|
64.4K
|
Q2 2025
Added 238496.3%
|
|
|
|
PUT
|
$474 Million
|
34.6K
|
Q2 2025
Added 71983.33%
|
|
|
|
PUT
|
$452 Million
|
12.4K
|
Q2 2025
New holding
|
|
Ultragenyx Pharmaceutical In
|
PUT
|
$392 Million
|
28K
|
Q2 2025
Added 8660.0%
|
|
|
|
CALL
|
$378 Million
|
362
|
Q2 2025
Added 23.55%
|
|
|
|
CALL
|
$353 Million
|
303
|
Q1 2025
New holding
|
|
|
|
CALL
|
$342 Million
|
1.74K
|
Q2 2025
New holding
|
|
|
|
CALL
|
$293 Million
|
560
|
Q2 2025
New holding
|
|
|
|
CALL
|
$248 Million
|
646
|
Q2 2025
New holding
|
|
|
|
CALL
|
$244 Million
|
3.04K
|
Q2 2025
New holding
|
|
|
|
PUT
|
$223 Million
|
59.8K
|
Q2 2025
Added 12383.72%
|
|
|
|
CALL
|
$183 Million
|
1.12K
|
Q2 2025
New holding
|
|
|
|
PUT
|
$174 Million
|
86.8K
|
Q2 2025
Added 361645.84%
|
|
|
|
CALL
|
$163 Million
|
403
|
Q2 2025
New holding
|
|
Ultragenyx Pharmaceutical In
|
CALL
|
$129 Million
|
500
|
Q2 2025
Added 85.19%
|
|
|
|
CALL
|
$106 Million
|
313
|
Q1 2025
New holding
|
|
|
|
CALL
|
$90.8 Million
|
230
|
Q2 2025
New holding
|
|
Credo Technology Group Holdi
|
CALL
|
$94.5 Million
|
140
|
Q2 2025
New holding
|
|
|
|
CALL
|
$74.6 Million
|
120
|
Q2 2025
New holding
|
|
|
|
CALL
|
$81.6 Million
|
297
|
Q2 2025
Added 135.71%
|
|
|
|
CALL
|
$64.4 Million
|
66
|
Q2 2025
New holding
|
|
|
|
CALL
|
$73.6 Million
|
1.93K
|
Q1 2025
New holding
|
|
|
|
CALL
|
$71.6 Million
|
250
|
Q2 2025
New holding
|
|
|
|
CALL
|
$73.4 Million
|
258
|
Q1 2025
New holding
|
|
Agios Pharmaceuticals Inc
|
CALL
|
$63.5 Million
|
316
|
Q2 2025
Added 1.94%
|
|
|
|
CALL
|
$64.5 Million
|
418
|
Q1 2025
New holding
|
|
Recursion Pharmaceuticals In
|
CALL
|
$61.8 Million
|
1.61K
|
Q1 2025
New holding
|
|
|
|
CALL
|
$53.6 Million
|
140
|
Q2 2025
New holding
|
|
|
|
CALL
|
$53.4 Million
|
2.91K
|
Q2 2025
Added 202.81%
|
|
|
|
CALL
|
$55.4 Million
|
461
|
Q2 2025
New holding
|
|
|
|
CALL
|
$55.8 Million
|
175
|
Q2 2025
Added 191.67%
|
|
|
|
CALL
|
$57.4 Million
|
262
|
Q2 2025
Added 445.83%
|
|
Acadia Pharmaceuticals Inc
|
CALL
|
$40.6 Million
|
204
|
Q2 2025
New holding
|
|
|
|
CALL
|
$42.8 Million
|
115
|
Q2 2025
Reduced 29.45%
|
|
Sellas Life Sciences Group I
|
CALL
|
$36.4 Million
|
920
|
Q2 2025
New holding
|
|
Terns Pharmaceuticals Inc
|
CALL
|
$35.3 Million
|
373
|
Q2 2025
New holding
|
|
|
|
CALL
|
$37.9 Million
|
239
|
Q2 2025
Reduced 32.49%
|
|
|
|
CALL
|
$46.1 Million
|
160
|
Q2 2025
New holding
|
|
|
|
CALL
|
$28.9 Million
|
40
|
Q2 2025
New holding
|
|
|
|
PUT
|
$30.5 Million
|
873
|
Q2 2025
New holding
|
|
|
|
CALL
|
$24.3 Million
|
230
|
Q2 2025
New holding
|
|
|
|
CALL
|
$25.7 Million
|
249
|
Q2 2025
Added 85.82%
|
|
|
|
CALL
|
$20.5 Million
|
479
|
Q1 2025
New holding
|
|
